치료 및 진단 표적으로서의 HLA-H, HLA-J, HLA-L, HLA-V 및 HLA-Y

• Main Authors: WINTERHALTER CHRISTOPH, WURFEL WOLFGANG, WURFEL FRANZISKA, WIRTZ RALPH MARKUS
• Format: Patent
• Language: Korean
• Published: 28.06.2022
• Subjects: BEER; BIOCHEMISTRY; CHEMISTRY; COMPOSITIONS OR TEST PAPERS THEREFOR; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL ORENZYMOLOGICAL PROCESSES; ENZYMOLOGY; INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES; MEASURING; MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEICACIDS OR MICROORGANISMS; METALLURGY; MICROBIOLOGY; MUTATION OR GENETIC ENGINEERING; ORGANIC CHEMISTRY; PEPTIDES; PHYSICS; PROCESSES OF PREPARING SUCH COMPOSITIONS; SPIRITS; TESTING; VINEGAR; WINE

본 발명은 대상체에서 종양의 치료 또는 예방을 위한 약제(medicament) 또는 대상체에서 종양 검출을 위한 진단제(diagnostic agent)의 제조방법에 관한 것으로 (A) 상기 대상체로부터 얻은 샘플에서 HLA-H, HLA-J, HLA-L, HLA-V 또는 HLA-Y와 적어도 85% 동일한 적어도 하나의 핵산 분자 및/또는 적어도 하나의 단백질 또는 펩티드의 발현을 결정하는 단계를 포함하되, 핵산 분자는 상기 단백질 또는 폴리펩티드를 인코딩하거나 적어도 150개의 뉴클레오티드를 포함하는 핵산 단편으로 이뤄지고, 및 (B) 대상체에서 적어도 하나의 핵산 분자 및/또는 적어도 하나의 단백질 또는 펩티드의 발현을 억제할 수 있는 약제를 제조하는 단계 및/또는 대상체에서 적어도 하나의 핵산 분자 및/또는 적어도 하나의 단백질 또는 펩티드의 발현 부위를 생체 내에서 검출할 수 있는 진단제를 제조하는 단계를 포함한다. The present invention relates to a method for producing a medicament for the treatment or prevention of a tumor in a subject or a diagnostic agent for the detection of a tumor in a subject comprising (A) determining the expression of at least one nucleic acid molecule and/or at least one protein or peptide in a sample obtained from said subject, wherein the at least one nucleic acid molecule is selected from nucleic acid molecules (a) encoding a polypeptide comprising or consisting of the amino acid sequence of any one of SEQ ID NOs 1 to 5, (b) comprising or consisting of the nucleotide sequence of any one of SEQ ID NOs 6 to 10, (c) encoding a polypeptide which is at least 85% identical, preferably at least 90% identical, and most preferred at least 95% identical to the amino acid sequence of (a), (d) consisting of a nucleotide sequence which is at least 95% identical, preferably at least 96% identical, and most preferred at least 98% identical to the nucleotide sequence of (b), (e) consisting of a nucleotide sequence which is degenerate with respect to the nucleic acid molecule of (d), (f) consisting of a fragment of the nucleic acid molecule of any one of (a) to (e), said fragment comprising at least 150 nucleotides, preferably at least 300 nucleotides, more preferably at least 450 nucleotides, and most preferably at least 600 nucleotides, and (g) corresponding to the nucleic acid molecule of any one of (a) to (f), wherein T is replaced by U, and wherein the at least one protein or peptide is selected from proteins or peptides being encoded by the nucleic acid molecule of any one of (a) to (g); and (B) producing a medicament capable of inhibiting the expression of the at least nucleic acid molecule and/or the at least one protein or peptide in the subject, if the at least one nucleic acid molecule and/or at least one protein or peptide is expressed in (A), and/or (B′) producing a diagnostic agent capable of detecting in vivo the sites of expression of the at least nucleic acid molecule and/or the at least one protein or peptide in the subject, if the at least one nucleic acid molecule and/or at least one protein or peptide is expressed in (A).